Over 15 years of experience in translational medicine and biomarker development within academic and pharmaceutical settings. Member of translational research teams that contributed to the approvals of KEYTRUDA® (Pembrolizumab, anti-PD-1 therapy) for melanoma, YERVOY® (Ipilimumab, anti-CTLA4 therapy) for melanoma, NULOJIX® (Belatacept, anti-CTLA4 therapy) for kidney transplantation.

Scientific Director, Oncology Translational Research @ From September 2015 to Present (4 months) Director, Molecular Biomarkers and Diagnostics, Early Development and Discovery Sciences @ From May 2011 to April 2015 (4 years) Associate Director, Discovery Medicine & Clinical Pharmacology @ From May 2010 to May 2011 (1 year 1 month) Principal Scientist, Head of Clinical Biomarkers-Flow Cytometry @ From August 2007 to 2010 (3 years) Senior Research Investigator, Clinical Discovery Technology @ From June 2005 to July 2007 (2 years 2 months) Research Scientist, Tumor Immunology @ • Investigated cell-mediated immune mechanisms in Tumor Immunology. • Contributed to research proposals that secured $6M in NIH grants. From April 2002 to June 2005 (3 years 3 months) Research Fellow, Alan Houghton Laboratory, Sloan-Kettering Institute @ Research Project: NKT cell-mediated immune response against tumor antigens on melanoma. From August 1999 to April 2002 (2 years 9 months)

PhD, Immunology @ The University of Connecticut Health Center From 1992 to 1998 M.D., Medicine @ Shanghai Medical University From 1986 to 1992 Dianna Wu is skilled in: Biomarkers, Checkpoint inhibitor, Immunology, Clinical flow cytometry, Drug Development, Biomarker assay development, IHC, Translational research, Companion diagnostics, CRO biomarker assay outsourcing, Immuno-Oncology, Biomarker Discovery, Biotechnology, Clinical Development, Laboratory